Insurers balk at covering GYN treatment by OhioHealth
The Columbus Dispatch, October 8, 2012
OhioHealth recently spent $3.5 million on equipment for a less-invasive treatment of benign but sometimes problematic tumors that grow on the uterus. And the health system has spent additional money to advertise the outpatient uterine-fibroid procedure, which was approved by the U.S. Food and Drug Administration eight years ago. OhioHealth officials said they anticipated some initial push-back from insurers to paying for the procedure, which OhioHealth had expected to perform 80 to 100 times a year by 2014. But the reluctance, they said, has been far greater than expected from health insurers such as Anthem, Aetna and Medical Mutual of Ohio.
Most Viewed
Most Emailed
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- House Lawmakers Grill CMS Over Health Exchange Navigators
- How Chargemaster Data May Affect Hospital Revenue
- Fortunately, Angelina Jolie Isn't On Medicare
- Don't Let Nurses Sink Your Bottom Line
- Insurer's App Aims to Lower Healthcare Costs, Securely
- Primary Care Docs Average More Hospital Revenue Than Specialists
- ED Physicians Key to Half of Hospital Admissions
- Uncompensated Care Faces a Double Hit in Some States
- Hospital Pricing Transparency a Marketing Game Changer
